Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H32N2 |
| Molecular Weight | 240.428 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 2 |
SHOW SMILES / InChI
SMILES
C[N+]2(CCCCC[N+]1(C)CCCC1)CCCC2
InChI
InChIKey=XSBSKEQEUFOSDD-UHFFFAOYSA-N
InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2
| Molecular Formula | C15H32N2 |
| Molecular Weight | 240.428 |
| Charge | 2 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pentolinium (brand name Ansolysen) is a ganglionic cholinergic antagonist, acting on alpha 3 beta 4 neuronal nicotinic acetylcholine receptors (nAChRs). It was used as an antihypertensive drug during surgery or to control hypertensive crises, but Ansolysen was discontinued. Pentolinium inhibits release of adrenaline and noradrenaline from adrenergic nerves.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years |
Other AEs: Dizziness, Constipation... Other AEs: Dizziness Sources: Constipation Vomiting Paralytic ileus (grade 5) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Constipation | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years |
|
| Dizziness | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years |
|
| Vomiting | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years |
|
| Paralytic ileus | grade 5 | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Role of sympathetic tone in BSO-induced hypertension in mice. | 2010-08 |
|
| The role of nitric oxide in the development of neurogenic pulmonary edema in spinal cord-injured rats: the effect of preventive interventions. | 2009-10 |
|
| Role of the sympathetic nervous system in Schlager genetically hypertensive mice. | 2009-10 |
|
| Cardiovascular effects of noradrenaline microinjection into the medial part of the superior colliculus of unanesthetized rats. | 2009-09-22 |
|
| Enhanced responses to ganglion blockade do not reflect sympathetic nervous system contribution to angiotensin II-induced hypertension. | 2009-09 |
|
| Role of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors in the cardiovascular effects of L-glutamate microinjection into the hypothalamic paraventricular nucleus of unanesthetized rats. | 2009-07 |
|
| Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa. | 2009-04 |
|
| Mechanisms involved in the pressor response to noradrenaline microinjection into the supraoptic nucleus of unanesthetized rats. | 2009-01-28 |
|
| Neuronal source of plasma dopamine. | 2008-11 |
|
| Levels of renal and extrarenal sympathetic drive in angiotensin II-induced hypertension. | 2008-04 |
|
| Release of acetylcholine by syringin, an active principle of Eleutherococcus senticosus, to raise insulin secretion in Wistar rats. | 2008-03-28 |
|
| Cardiovascular responses to noradrenaline microinjection in the ventrolateral periaqueductal gray of unanesthetized rats. | 2008-02-15 |
|
| Vasorelaxant activity of some oxime derivatives. | 2007-12-01 |
|
| Angiotensin II-based hypertension and the sympathetic nervous system: the role of dose and increased dietary salt in rabbits. | 2007-09 |
|
| Cardiovascular effects of noradrenaline microinjection in the bed nucleus of the stria terminalis of the rat brain. | 2007-05-15 |
|
| Cardiovascular effects of L-glutamate microinjection in the supraoptic nucleus of unanaesthetized rats. | 2007-05 |
|
| Cardiovascular effects of carbachol microinjected into the bed nucleus of the stria terminalis of the rat brain. | 2007-04-27 |
|
| Total peripheral resistance responsiveness during the development of secondary renal hypertension in dogs. | 2007-03 |
|
| The participation of brain NO synthase in blood pressure control of adult spontaneously hypertensive rats. | 2007-03 |
|
| Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats. | 2006-12 |
|
| Pressor effects of noradrenaline injected into the lateral septal area of unanesthetized rats. | 2006-11-29 |
|
| Effects of chronic treatment with 7-nitroindazole in hyperthyroid rats. | 2006-11 |
|
| Release of acetylcholine by Hon-Chi to raise insulin secretion in Wistar rats. | 2006-08-14 |
|
| Release of acetylcholine to raise insulin secretion in Wistar rats by oleanolic acid, one of the active principles contained in Cornus officinalis. | 2006-08-14 |
|
| Baroreceptor reflex stimulation does not induce cytomegalovirus promoter-driven transgene expression in the ventrolateral medulla in vivo. | 2006-06-30 |
|
| Increase of insulin secretion by ginsenoside Rh2 to lower plasma glucose in Wistar rats. | 2006-02-01 |
|
| Cardiovascular effects of noradrenaline microinjected into the dorsal periaqueductal gray area of unanaesthetized rats. | 2005-12 |
|
| Pressor and tachycardic responses evoked by microinjections of L-glutamate into the medial prefrontal cortex of unanaesthetized rats. | 2005-05 |
|
| Peptide YY administration into the posterior hypothalamic nucleus of the rat evokes cardiovascular changes by non-adrenergic, non-cholinergic mechanisms. | 2005-04 |
|
| Role of bradykinin B2-receptor in the sympathoadrenal effects of 'new pressor protein' related to human blood coagulation factor XII fragment. | 2004-06 |
|
| Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. | 2004-05 |
|
| Fenfluramine-induced hypothermia is associated with cutaneous dilation in conscious rats. | 2004-02 |
|
| Vasoactive systems in L-NAME hypertension: the role of inducible nitric oxide synthase. | 2004-01 |
|
| The role of renal sympathetic nervous system in the pathogenesis of ischemic acute renal failure. | 2003-11-28 |
|
| Catecholamine and oxytocin cells respond to hypovolaemia as well as hypotension. | 2003-08-06 |
|
| Resolving the composite trait of hypertension into its pharmacogenetic determinants by acute pharmacological modulation of blood pressure regulatory systems. | 2003-01 |
|
| Central cardiovascular action of urotensin II in conscious rats. | 2003-01 |
|
| Gender-specific genetic determinants of blood pressure and organ weight: pharmacogenetic approach. | 2003 |
|
| Human coagulation factor XII-related "new pressor protein": role of PACAP in its cardiovascular and sympathoadrenal effects. | 2002-10 |
|
| Sympathetic activation by fenfluramine depletes brown adipose tissue norepinephrine content in rats. | 2002-10 |
|
| Release of acetylcholine by Die-Huang-Wan to enhance insulin secretion for lowering plasma glucose in Wistar rats. | 2002-09-30 |
|
| Short exposure of maturing, bone marrow-derived dendritic cells to norepinephrine: impact on kinetics of cytokine production and Th development. | 2002-08 |
|
| In vivo effects of fenoldopam on autonomic nervous system after inhibition or activation of ganglionic transmission. | 2002-05-31 |
|
| The altered balance between sympathetic nervous system and nitric oxide in salt hypertensive Dahl rats: ontogenetic and F2 hybrid studies. | 2002-05 |
|
| Chronic central infusion of orexin-A increases arterial pressure in rats. | 2002-03-15 |
|
| Altered balance of main vasopressor and vasodepressor systems in rats with genetic hypertension and hypertriglyceridaemia. | 2002-03 |
|
| Sympathetic blockade significantly improves cardiovascular alterations immediately after spinal cord injury in rats. | 2002-02-15 |
|
| Noradrenaline and the kidney: friends or foes? | 2001-12 |
|
| Central human cocaine- and amphetamine-regulated transcript peptide 55-102 increases arterial pressure in conscious rabbits. | 2001-11 |
|
| Central orexin-A augments sympathoadrenal outflow in conscious rabbits. | 2001-06 |
Sample Use Guides
intramuscularly: 1 to 2 0.25-mg ampoules
Ansolysen must be used with caution. The initial dose is from 20-40 mg., taken 15 to 20 minutes before each meal and at bedtime, to ensure an even digestive absorption. Each dose is increased by 20-40 mg. four times a day at intervals of five to seven days until the desired hvpotensive effect is obtained. The maintenance dose varies generally between 160 and 800 mg. a day.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:42 GMT 2025
by
admin
on
Mon Mar 31 18:21:42 GMT 2025
|
| Record UNII |
ULL76WPU5X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66886
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2096
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
Pentolinium
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
347401
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
SUB03692MIG
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
DTXSID5048554
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
144-44-5
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
5850
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
C77367
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
100000085527
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
DB01090
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY | |||
|
ULL76WPU5X
Created by
admin on Mon Mar 31 18:21:42 GMT 2025 , Edited by admin on Mon Mar 31 18:21:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
